Education
About Us
Working with TipRanks
Follow Us
Biodesix (BDSX)
NASDAQ:BDSX
BDSX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.17 - $2.04
Previous CloseN/A
Volume171.18K
Average Volume (3M)17.14M
Market Cap
$41.30M
Enterprise Value$94.89M
Total Cash (Recent Filing)$17.60M
Total Debt (Recent Filing)$62.28M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Aug 12, 2025EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding146,563,030
10 Day Avg. Volume2,067,589
30 Day Avg. Volume17,140,319
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)4.54
Price to Sales (P/S)0.00
P/FCF Ratio-1.11
Enterprise Value/Market Cap2.30
Enterprise Value/Revenue0.35
Enterprise Value/Gross Profit1.63
Enterprise Value/Ebitda-0.81
Forecast
1Y Price Target
$1.88Price Target Upside526.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Biodesix News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company expects to achieve adjusted EBITDA positivity and cash flow breakeven thereafter, providing a positive outlook for financial stability.
Market StrategyWith its tests addressing a large TAM delivering differentiated utility, the analyst reiterates a Buy recommendation.
Product DevelopmentBiodesix is exploring the addition of digital diagnostics and radiomics to its portfolio, which could enhance its long-term growth potential.
Bears Say
Revenue GuidanceBiodesix decreased its 2025 revenue guidance to $80-85 million from $92-95 million, indicating a reduction in expected revenue growth.
Sales Force ChallengesThe company's performance was impacted by meaningful decreases to the sales force and slower hiring of new sales reps.
Stock PerformanceShares have been under pressure, likely due to rocky results and general weakness in the space.
Options Prices
Currently, No data available
---
Ownership Overview
49.35% Insiders
3.36% Mutual Funds
26.29% Other Institutional Investors
18.42% Public Companies and Individual Investors
BDSX FAQ
What was Biodesix’s price range in the past 12 months?
Biodesix lowest stock price was $0.17 and its highest was $2.04 in the past 12 months.
What is Biodesix’s market cap?
Biodesix’s market cap is $41.30M.
When is Biodesix’s upcoming earnings report date?
Biodesix’s upcoming earnings report date is Aug 12, 2025 which is in 64 days.
How were Biodesix’s earnings last quarter?
Biodesix released its earnings results on May 13, 2025. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.07 by -$0.01.
Is Biodesix overvalued?
According to Wall Street analysts Biodesix’s price is currently Undervalued.
Does Biodesix pay dividends?
Biodesix does not currently pay dividends.
What is Biodesix’s EPS estimate?
Biodesix’s EPS estimate is -0.07.
How many shares outstanding does Biodesix have?
Biodesix has 146,563,030 shares outstanding.
What happened to Biodesix’s price movement after its last earnings report?
Biodesix reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.07. Following the earnings report the stock price went down -38.889%.
Which hedge fund is a major shareholder of Biodesix?
Currently, no hedge funds are holding shares in BDSX
Biodesix Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1.88 (526.67% Upside)
$1.88 (526.67% Upside)
Blogger Sentiment
Bullish
BDSX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▲ 56.1%
Last 30 Days ▲ 56.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-76.76%
12-Months-Change
Fundamentals
Return on Equity
-1454.41%
Trailing 12-Months
Asset Growth
-1.10%
Trailing 12-Months
Company Description
Biodesix
Biodesix, Inc. (BDSX) is a leading biotechnology company specializing in the development and commercialization of blood-based diagnostic solutions. Focused primarily on the oncology sector, the company offers a suite of diagnostic tests that help clinicians make more informed decisions about patient care. These tests are designed to improve outcomes for patients with lung cancer by providing insights into the disease's progression and response to treatment.
BDSX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth, operational efficiency, and significant advancements in development services and pipeline progress. However, these positive aspects were balanced by challenges in sales force reconfiguration and primary care market expansion, leading to a downward adjustment in revenue guidance.Read More>BDSX Stock 12 Month Forecast
Average Price Target
$1.88
▲(526.67%Upside)